Journals / Osteoporoz Dünyasından / 2003 / Cilt: 9 - Sayı: 2

Impact of risedronate on bone mineral density and quality of life in postmenopausal women with osteoporosis: The results of 1-year follow up

Postmenopozal osteoporozu olan kadınlarda risedronatın kemik mineral yoğunluğu ve yaşam kalitesi üzerine etkisi: 1 yıllık takip sonuçları

Pages
69–73
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, by increasing the bone mineral density, risedronate increases the quality of bone, decreases the risk of fracture and pain, and positively effects the quality of life.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Our objective was to assess the impact of treatment with risedronate on the bone mineral density and quality of life in the women who had postmenopausal osteoporosis (PMO).
📊
Key Findings & Data:Fortyfive of them were selected randomly, and constituted the study group while the remaining 20 served as control.
💡
Conclusion & Impact:In conclusion, by increasing the bone mineral density, risedronate increases the quality of bone, decreases the risk of fracture and pain, and positively effects the quality of life.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Osteoporoz · postmenopozal · Sağlık durumu göstergeleri

Abstract

Our objective was to assess the impact of treatment with risedronate on the bone mineral density and quality of life in the women who had postmenopausal osteoporosis (PMO). Sixtyfive patients with PMO were included in the study. Fortyfive of them were selected randomly, and constituted the study group while the remaining 20 served as control. Fortyfive patients comprising the study group were treated with 5 mg risedronate and 1000 mg calcium for 1 year while 20 control patients were treated only with 1000 mg calcium. The quality of life of the patients was evaluated with Notthingham Health Profile (NHP) scale both at the beginning and at the end of the study. Bone mineral densities were measured in the vertebral and femoral regions using DEXA at the beginning, and at 6th and 12th months of the treatment. The results of patients and controls were not different significantly after 6 months follow up (p>0.05). At the end of 1 year follow up, the bone mineral density of the treatment group increased significantly while it decreased significantly in the controls (p<0.05). Quality of life increased significantly in the treatment group (p<0.05) while it did not change in the control group (p>0.05). The parameters related to the limitation of physical activity did not change significantly in the treatment group (p>0.05). In conclusion, by increasing the bone mineral density, risedronate increases the quality of bone, decreases the risk of fracture and pain, and positively effects the quality of life.

Özet

Çalışmamızın amacı, PMO'u olan kadınlarda risedronat tedavisinin, kemik mineral yoğunluğu (KMY) ve yaşam kalitesi üzerindeki etkisini araştırmaktır. Çalışmaya PMO olan 65 hasta alındı. Rast gele yöntemle 45 olgu tedavi ve 20 olgu kontrol grubuna seçildi. Tedavi grubunu oluşturan 45 olguya 1 yıl süreyle, günlük 5 mg risedronat ve 1000 mg kalsiyum, kontrol grubundaki 20 olguya ise günlük 1000 mg kalsiyum verildi. Çalışmanın başlangıcında ve sonunda olguların yaşam kalitesini Nottingham Sağlık Profili (NSP) skalası ile değerlendirildi. Olguların kemik mineral yoğunlukları, tedavinin başında, 6.ayda ve 12.ayda vertebra ve femur bölgelerinden DEXA ile ölçüldü. İlk 6 aylık sürenin sonunda hasta ve kontrol gurubu ölçümleri arasında anlamlı bir fark saptanmadı (p>0.05). Bir yılın sonunda tedavi grubundaki olguların KMY ölçümlerinde anlamlı bir artış olduğu saptanırken (p 0.05). Tedavi grubundaki olgularda, fiziksel aktivite kısıtlılığı parametresinde anlamlı bir farklılık bulunmadı (p>0.05). Sonuç olarak; risedronatın kemik mineral yoğunluğunu arttırdığı, kırık riskini azalttığı, ağrıyı azalttığı ve yaşam kalitesinin artmasında etkili olduğu kanısına vardık.

🔖

Cite This Article

MADENCİ, E., GÜRSOY, S., KEVEN, S., ARICA, E. (2003). Impact of risedronate on bone mineral density and quality of life in postmenopausal women with osteoporosis: The results of 1-year follow up. Osteoporoz Dünyasından, Cilt: 9 - Sayı: 2, 69–73. https://ajindex.com/articles/286790

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Eskiyurt N, Akyüz G: Osteoporoz: Genel bir değerlendirme. Karaaslan Y, Akyüz G, (Ed) Osteoporoz Top 40. MD Yayıncılık, Ankara 2002; s:1-22 2. Kanis JA, Delmas P, Burckhardt P, et al. Guidelines for diagnosis and management of osteoporosis. Osteoporosis Int 1997; 7: 390-406 3. WHO Study Group: Assesment of fracture risk and its application to screening for postmenopousal osteoporosis. World Health Organization, Geneva, 1994 4. Consensus Development Conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am Med J 1993; 94: 646-50 5. Devide G, Silvano A: New bisphosphonates in the treatment of bone disease. Drugs & Aging 1999; 15(4): 285-93 6. Lieata AA. Bisphosphonate therapy. Am J Med Sci 1997; 313: 17-22 7. Richardson AC, Tinling SP, Chole RA. Risedronate activity in the fetal and neonatal mouse. Otolaryngol Head Neck Surg 1993; 109: 623-33 8. Mitchell DY, Barr WH, Eusebio RA, et al. Determination of intravenous pharmacokinetics, absolute and relative bioavailability and intra and intersubject variability of risedronate using a four period replicate study design (abstract no. 3444). Pharm Res 1997; 14: 610 9. Blank MA, Ema BL, Gibson GW, et al. Nonclinical model for assessing gastric effects of bisphosphonates. Dig Dis Sci 1997; 42: 281-8 10. Mitchell DY, Eusebio RA, Heise MA, et al. The effect of dosing regimen on the pharmacokinetics of risedronate administered to healty subjects (abstract no. M661). J Bone Miner Res 1996; 11: s:347 11. Sindel D, Dilşen G, Kubat A. Postmenopozal osteoporozda yaşam kalitesi sonuçları. Romatol Tıb Rehab 1995; 6 (3); 144-8. 12. Adami S, Baroni MC, Pedrazzoni M, et al. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteoporosis Int 1993; suppl.3: 21-7 13. Mortensen L, Charles P, Bekler PJ, et al. Risedronate in bone mass in an early postmenopausal population: Treatment plus one year of follow up. J Clin An Metab 1998; 83 (2): 396-402 14. Steven TH, Nelson BW, Harry KG, Clark DM, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. Jama 1999; 282 (14): 1344-52 15. Akyüz G. Osteoporozda ağrı ve osteoporozun yaşam kalitesi üzerine etkileri. Prospect; 1998; 3: 130-2 16. Lips P, Agnusdei D, Caulin F et al. The development of a European questionnaire for quality of life in patients with vertebral osteoporosis. J Rheumatol Suppl, 103;84-85; discussion